Aminobutyric Acid Receptors

Total Page:16

File Type:pdf, Size:1020Kb

Aminobutyric Acid Receptors Commentary Absinthe and ␥-aminobutyric acid receptors Richard W. Olsen* Department of Molecular and Medical Pharmacology, University of California School of Medicine, Los Angeles, CA 90095-1735 bsinthe is an emerald-green liqueur style led to a negative reaction and major Athat achieved fantastic popularity at support for prohibition in France and the close of the 19th century. It was asso- elsewhere. One can see the negative side ciated with the Bohemian lifestyle and was of absinthe drinking in many of the poems credited with the inspiration of famous written about it and the pictures drawn artists and poets (1, 2). Because of its about it, as in Degas (Fig. 1). The ‘‘mad- widespread abuse and the associated tox- ness in a bottle,’’ i.e., absinthe, was doubly icity of its content of oil of wormwood, attacked for its reputation for inducing absinthe was made illegal in most coun- insane and criminal acts, as well as con- tries in the 1910s. The most likely ingre- vulsions and other toxicity (2). However, dient responsible for toxicity is believed to statistics showed that in France in 1907, be the terpenoid ␣-thujone (1–4). Oil of only about 1/40th of the inmates of insane wormwood has convulsant activity as well asylums were absinthe drinkers, and many as activity in killing worms and insects (5). of those would actually drink anything The mechanism of action of thujone has alcoholic (2). remained speculative until now. In a re- Finally, military and civilian leaders cent issue of PNAS, Hold et al. (6) pro- entering into World War I discouraged vided evidence that thujone acts as a alcohol abuse and absinthe in support of ␥ -aminobutyric acid type A (GABAA) the war effort. Absinthe was outlawed in receptor chloride channel blocker, much most countries in 1910–1915, and all like the plant convulsant picrotoxin, and alcohol became illegal shortly after in related synthetic analogs. many. Pernod, an anise-flavored, green- Absinthe use is ritualistic, involving a colored analog of absinthe lacking the oil special glass and perforated spoon and of wormwood, has remained available. Fig. 1. L’Absinthe, E. Degas. COMMENTARY adding cold water by pouring it over Absinthe can still be purchased in certain sugar cubes, at which time the liqueur lands, including Czechoslovakia, and you thujone (Fig. 2), and its only pharmaco- turns white because of precipitation of can make your own with readily available logical action listed in the Merck index is alcohol-soluble herbal ingredients. Its and legal ingredients (check the web). ‘‘convulsant’’ (8). Many naturally occur- magical powers worshiped by the masses, Absinthe was widely regarded as im- ring and synthetic convulsive agents are absinthe became the national drink of parting pharmacological effects beyond blockers of GABA-mediated inhibition France in the late 19th century, with those of alcohol alone, such as stimulating (9, 10). The prototypic GABA channel workers and artists alike awaiting l’heure the imagination and aphrodisiac action, as verte, 5–7 p.m., when they all headed for well as producing hallucinations. Except blocker picrotoxinin (Fig. 2) is isolated the cafes of Paris for their glass of ab- for the toxicity, there is little research from plants of the moonseed family, sinthe, drinking 36–221 million liters per evidence supporting this view and more Menispermaceae, and its close relatives year around 1910 (1, 2). In 1906, Paris study is needed. tutin and coriamyrtin, from the New had 33,330 bars (and drink sellers) for As noted, oil of wormwood had an- Zealand tutu plant Coriaria arborea (11, 2,601,000 people, compared with 17,000 cient herbal medicinal uses, primarily for 12), known as a ‘‘loco weed’’ that caused bakers. Alcohol was a major economic digestion (5). It is an extract of the occasional poisonings in cows, and even force. The major supplier was the Swiss common European woody bush, the in people. factory Pernod, established in 1787, and wormwood plant, Artemisia absinthium. The senior author of this thujone re- the original French connection was prob- Other members of the Artemisia genus port, Dr. John Casida, has synthesized and ably in Algeria. include sagebrush. The natural product studied a major category of synthetic po- Many Parisians adopted the Bohemian thujone is found in plants of the Thuja tent neurotoxic chemicals (13), the cage lifestyle in the Belle Epoque, among them genus, which is arborvitae and cedar. convulsants (Fig. 2), which were discov- many creative artists and writers. De Mus- They are in the conifer family Cupressa- ered to be noncompetitive GABAA recep- set was so often hung over from absinthe cae, which also includes Juniperus (the tor antagonists acting at the picrotoxinin that his students found him to ‘‘absinthe source of gin), and nutmeg; the related site (13–15). One of these drugs, t-butyl himself too much from his lectures.’’ Tsuga genus is hemlock (a well-known bicylcophosphorothionate (TBPS), is a Beaudelaire was an habitual user of ab- poison). major research tool used to assay GABA sinthe. Verlaine abused absinthe in a self- The newly noted connection with receptors by radioligand binding (16). destructive overindulgence, in the midst of GABAA receptor channel antagonism Synthetic butyrolactones with convulsant a homosexual affair with Rimbaud. Other should not be surprising in light of pre- big fans included Zola, Oscar Wilde, Gau- vious observations. The major pharma- gin, Toulouse-Lautrec, van Gogh, and Pi- cological effect of oil of wormwood is See companion article on page 3826 in issue 8 of volume 97. casso. But the wild and destructive life- seizures (2). The active agent (1, 7) is *E-mail: [email protected]. PNAS ͉ April 25, 2000 ͉ vol. 97 ͉ no. 9 ͉ 4417–4418 Downloaded by guest on October 1, 2021 of evidence: (i) the symptoms of poisoning Now why would a drug with toxic and and protection by benzodiazepines and convulsant actions possibly be considered barbiturates resemble those of other pleasant or at least desirable? A specula- GABA blockers like picrotoxinin; (ii)a tion that thujone might behave in a man- strain of insects resistant to picrotoxin and ner similar to tetrahydrocannabinol, the GABA-blocking insecticides like dieldrin active ingredient of marijuana, was ruled is resistant to thujone; (iii) thujone com- out (22): thujone has a low affinity for petitively inhibits the binding of a radio- cannabinoid receptor binding sites but none of the pharmacological actions, such active cage convulsant to the picrotoxin/ as locomotor activity (open field test), convulsant site on GABA receptors in A immobility (ring stand test), and analgesia mammalian brain membranes; and (iv) (hot plate test). Thus cannabinoids, but thujone reversibly blocks GABAA recep- not thujone, are central nervous system tor chloride currents in mammalian neu- depressants, like a sleeping pill. Thujone, rons. These actions are shown not to be like picrotoxin, is excitatory on the brain caused by ethanol. In addition, the authors (analeptic). Such an agent may produce demonstrate the nature and activity of the mood elevation and antidepressant ef- major metabolites of thujone in mamma- fects. One may note the anxiogenic and Fig. 2. Chemical structures. lian brain and liver. They demonstrate that possibly alerting effect of GABA antago- ␣-thujone is 2.3 times more active than nists, as opposed to the anxiolytic, seda- ␤ tive, but also amnestic effects of GABA- and anticonvulsant actions also have been -thujone in binding and that 7-hydroxy- ␣-thujone and dehydro-␣-thujone are enhancing drugs like benzodiazepines and described for the picrotoxinin site (17). In ␣ ethanol (9, 10, 23). Do not forget, how- addition, this drug target appears to be the toxic but not as potent as -thujone. It would have been nice to have additional ever, that in absinthe one is balancing the site of action of the experimental convul- ␤ effect of thujone with the intoxicating, sant pentylenetetrazol (18) and numerous biological potencies for -thujone because it is more abundant than ␣-thujone in disinhibitory, and depressant effects of polychlorinated hydrocarbon insecticides, ethanol, not to mention those of the other ␣ wormwood and active in the binding test. including dieldrin (Fig. 2) and -endosul- herbal ingredients of oil of wormwood and If the two stereoisomers had differed in fan, mentioned in Hold et al. (6). This was others added to the myriad recipes for demonstrated independently by both Dr. activity it would have provided even stron- absinthe now in existence. Casida (19, 20) and another author of the ger evidence that the GABAA receptor is I will leave with this quote of Oscar report, Dr. Toshio Narahashi (21), who the drug target. It is possible or likely that Wilde about absinthe: ‘‘After the first has been a pioneer in mechanism studies both isomers have some activity. Likewise, glass, you see things as you wish they were. on many drugs and toxins. the high abundance of the metabolite After the second, you see them as they are The report of Hold et al. (6) convinc- 7-hydroxy thujone suggests the possibility not. Finally, you see things as they really ingly demonstrates that thujone acts as a that some of the pharmacological actions are, which is the most horrible thing in the GABAA receptor antagonist by four lines may ensue from this substance. world’’ (2). 1. Vogt, D. D. & Montagne, M. (1982) Int. J. Addict. 9. Macdonald, R. L. & Olsen R. W. (1994) Annu. 16. Squires, R. F., Casida, J. E., Richardson, M. & 17, 1015–1029. Rev. Neurosci. 17, 569–602. Saederup, E. (1983) Mol. Pharmacol. 23, 326–336. 2. Conrad, B. (1988) Absinthe: History in a Bottle 10. Olsen, R. W. & Gordey, M. (2000) in Handbook of 17. Klunk, W. E., Covey, D. F. & Ferrendelli, J.
Recommended publications
  • Picrotoxin-Like Channel Blockers of GABAA Receptors
    COMMENTARY Picrotoxin-like channel blockers of GABAA receptors Richard W. Olsen* Department of Molecular and Medical Pharmacology, Geffen School of Medicine, University of California, Los Angeles, CA 90095-1735 icrotoxin (PTX) is the prototypic vous system. Instead of an acetylcholine antagonist of GABAA receptors (ACh) target, the cage convulsants are (GABARs), the primary media- noncompetitive GABAR antagonists act- tors of inhibitory neurotransmis- ing at the PTX site: they inhibit GABAR Psion (rapid and tonic) in the nervous currents and synapses in mammalian neu- system. Picrotoxinin (Fig. 1A), the active rons and inhibit [3H]dihydropicrotoxinin ingredient in this plant convulsant, struc- binding to GABAR sites in brain mem- turally does not resemble GABA, a sim- branes (7, 9). A potent example, t-butyl ple, small amino acid, but it is a polycylic bicyclophosphorothionate, is a major re- compound with no nitrogen atom. The search tool used to assay GABARs by compound somehow prevents ion flow radio-ligand binding (10). through the chloride channel activated by This drug target appears to be the site GABA in the GABAR, a member of the of action of the experimental convulsant cys-loop, ligand-gated ion channel super- pentylenetetrazol (1, 4) and numerous family. Unlike the competitive GABAR polychlorinated hydrocarbon insecticides, antagonist bicuculline, PTX is clearly a including dieldrin, lindane, and fipronil, noncompetitive antagonist (NCA), acting compounds that have been applied in not at the GABA recognition site but per- huge amounts to the environment with haps within the ion channel. Thus PTX major agricultural economic impact (2). ͞ appears to be an excellent example of al- Some of the other potent toxicants insec- losteric modulation, which is extremely ticides were also radiolabeled and used to important in protein function in general characterize receptor action, allowing and especially for GABAR (1).
    [Show full text]
  • The Anxiomimetic Properties of Pentylenetetrazol in the Rat
    University of Rhode Island DigitalCommons@URI Open Access Dissertations 1980 THE ANXIOMIMETIC PROPERTIES OF PENTYLENETETRAZOL IN THE RAT Gary Terence Shearman University of Rhode Island Follow this and additional works at: https://digitalcommons.uri.edu/oa_diss Recommended Citation Shearman, Gary Terence, "THE ANXIOMIMETIC PROPERTIES OF PENTYLENETETRAZOL IN THE RAT" (1980). Open Access Dissertations. Paper 165. https://digitalcommons.uri.edu/oa_diss/165 This Dissertation is brought to you for free and open access by DigitalCommons@URI. It has been accepted for inclusion in Open Access Dissertations by an authorized administrator of DigitalCommons@URI. For more information, please contact [email protected]. THE ANXIOMIMETIC PROPERTIES OF PENTYLENETETRAZOL IN THE RAT BY GARY TERENCE SHEARMAN A DISSERTATION SUBMITTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY IN PHARMACEUTICAL SCIENCES (PHARMACOLOGY AND TOXICOLOGY) UNIVERSITY OF RHODE ISLAND 19 80 DOCTOR OF PHILOSOPHY DISSERT.A.TION OF GARY TERENCE SHEAffiil.AN Approved: Dissertation Cormnittee \\ Major Professor ~~-L_-_._dd__· _... _______ _ -~ar- Dean of the Graduate School UNIVERSITY OF RHODE ISLAND 1980 ABSTRACT Investigation of the biological basis of anxiety is ham­ pered by the lack of an appropriate animal model for research purposes. There are no known drugs that cause anxiety in laboratory animals. Pentylenetetrazol (PTZ) produces intense anxiety in human volunteers (Rodin, 1958; Rodin and Calhoun, 1970). Therefore, it was the major objective of this disser- tation to test the hypothesis that the discriminative stimu­ lus produced by PTZ in the rat was related to its anxiogenic action in man. It was also an objective to suggest the neuro- chemical basis for the discriminative stimulus property of PTZ through appropriate drug interactions.
    [Show full text]
  • GABA Receptors
    D Reviews • BIOTREND Reviews • BIOTREND Reviews • BIOTREND Reviews • BIOTREND Reviews Review No.7 / 1-2011 GABA receptors Wolfgang Froestl , CNS & Chemistry Expert, AC Immune SA, PSE Building B - EPFL, CH-1015 Lausanne, Phone: +41 21 693 91 43, FAX: +41 21 693 91 20, E-mail: [email protected] GABA Activation of the GABA A receptor leads to an influx of chloride GABA ( -aminobutyric acid; Figure 1) is the most important and ions and to a hyperpolarization of the membrane. 16 subunits with γ most abundant inhibitory neurotransmitter in the mammalian molecular weights between 50 and 65 kD have been identified brain 1,2 , where it was first discovered in 1950 3-5 . It is a small achiral so far, 6 subunits, 3 subunits, 3 subunits, and the , , α β γ δ ε θ molecule with molecular weight of 103 g/mol and high water solu - and subunits 8,9 . π bility. At 25°C one gram of water can dissolve 1.3 grams of GABA. 2 Such a hydrophilic molecule (log P = -2.13, PSA = 63.3 Å ) cannot In the meantime all GABA A receptor binding sites have been eluci - cross the blood brain barrier. It is produced in the brain by decarb- dated in great detail. The GABA site is located at the interface oxylation of L-glutamic acid by the enzyme glutamic acid decarb- between and subunits. Benzodiazepines interact with subunit α β oxylase (GAD, EC 4.1.1.15). It is a neutral amino acid with pK = combinations ( ) ( ) , which is the most abundant combi - 1 α1 2 β2 2 γ2 4.23 and pK = 10.43.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2015/0025060A1 Tamarkin Et Al
    US 2015.0025060A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2015/0025060A1 Tamarkin et al. (43) Pub. Date: Jan. 22, 2015 (54) FOAMABLE COMPOSITIONS AND KITS (30) Foreign Application Priority Data COMPRISING ONE ORMORE OF A CHANNEL AGENT, ACHOLINERGICAGENT, Oct. 25, 2002 (IL) .......................................... 1524.86 A NITRC OXDE DONOR AND RELATED AGENTS AND THEIR USES Publication Classification (71) Applicant: Foamix Pharmaceuticals Ltd., Rehovot (51) Int. Cl. (IL) A613 L/554 (2006.01) A 6LX3 L/505 (2006.01) (72) Inventors: Dov Tamarkin, Macabim (IL); Meir A647/10 (2006.01) Eini, Ness Ziona (IL); Doron Friedman, A613 L/4422 (2006.01) Karmei Yosef (IL); Tal Berman, Rishon (52) U.S. Cl. Le Ziyyon (IL); Alex Besonov, Rehovot CPC ........... A6 IK3I/554 (2013.01); A61 K3I/4422 (IL) (2013.01); A61 K3I/505 (2013.01); A61 K 47/10 (2013.01) (21) Appl. No.: 14/448,670 USPC ....................... 514/211.03: 514/356; 514/275 (22) Filed: Jul. 31, 2014 (57) ABSTRACT Related U.S. Application Data The present invention relates to a foamable therapeutic com position comprising: (a) a therapeutically effective concen (63) Continuation of application No. 1 1/767,442, filed on tration of at least one active agent selected from the group Jun. 22, 2007, which is a continuation-in-part of appli consisting of a channel agent, a cholinergic agent, and a nitric cation No. 10/911.367, filed on Aug. 4, 2004, said oxide donor; and (b) a foamable carrier comprising: application No. 1 1/767,442 is a continuation-in-part of i.
    [Show full text]
  • TRIDIONE® (Trimethadione) Tablets
    TRIDIONE® (trimethadione) Tablets BECAUSE OF ITS POTENTIAL TO PRODUCE FETAL MALFORMATIONS AND SERIOUS SIDE EFFECTS, TRIDIONE (trimethadione) SHOULD ONLY BE UTILIZED WHEN OTHER LESS TOXIC DRUGS HAVE BEEN FOUND INEFFECTIVE IN CONTROLLING PETIT MAL SEIZURES. DESCRIPTION TRIDIONE (trimethadione) is an antiepileptic agent. An oxazolidinedione compound, it is chemically identified as 3,5,5-trimethyloxozolidine-2,4-dione, and has the following structural formula: TRIDIONE is a synthetic, water-soluble, white, crystalline powder. It is supplied in tablets for oral use only. Inactive Ingredients 150 mg Dulcet Tablet: Corn starch, lactose, magnesium stearate, magnesium trisilicate, sucrose and natural/synthetic flavor. CLINICAL PHARMACOLOGY TRIDIONE has been shown to prevent pentylenetetrazol-induced and thujone-induced seizures in experimental animals; the drug has a less marked effect on seizures induced by picrotoxin, procaine, cocaine, or strychnine. Unlike the hydantoins and antiepileptic barbiturates, TRIDIONE does not modify the maximal seizure pattern in patients undergoing electroconvulsive therapy. TRIDIONE has a sedative effect that may increase to the point of ataxia when excessive doses are used. A toxic dose of the drug in animals (approximately 2 g/kg) produced sleep, unconsciousness, and respiratory depression. Trimethadione is rapidly absorbed from the gastrointestinal tract. It is demethylated by liver microsomes to the active metabolite, dimethadione. Approximately 3% of a daily dose of TRIDIONE is recovered in the urine as unchanged drug. The majority of trimethadione is excreted slowly by the kidney in the form of dimethadione. INDICATIONS TRIDIONE (trimethadione) is indicated for the control of petit mal seizures that are refractory to treatment with other drugs. CONTRAINDICATIONS TRIDIONE is contraindicated in patients with a known hypersensitivity to the drug.
    [Show full text]
  • Vimpat, INN-Lacosamide
    European Medicines Agency Evaluation of Medicines for Human Use Doc.Ref.: EMEA/460925/2008 ASSESSMENT REPORT FOR Vimpat International Nonproprietary Name: lacosamide Procedure No. EMEA/H/C/000863 Assessment Report as adopted by the CHMP with all information of a commercially confidential nature deleted. 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 75 23 70 51 E-mail: [email protected] http://www.emea.europa.eu © European Medicines Agency, 2008. Reproduction is authorised provided the source is acknowledged TABLE OF CONTENTS Page 1. BACKGROUND INFORMATION ON THE PROCEDURE........................................... 3 1.1 Submission of the dossier ........................................................................................................ 3 1.2 Steps taken for the assessment of the product.......................................................................... 3 2 SCIENTIFIC DISCUSSION................................................................................................. 4 2.1 Introduction.............................................................................................................................. 4 2.2 Quality aspects......................................................................................................................... 4 2.3 Non-clinical aspects............................................................................................................... 11 2.4 Clinical aspects .....................................................................................................................
    [Show full text]
  • Pentetrazol for Idiopathic Hypersomnia and Narcolepsy Type 2 NIHRIO (HSRIC) ID: 11738 NICE ID: 9624
    NIHR Innovation Observatory Evidence Briefing: February 2018 Pentetrazol for idiopathic hypersomnia and narcolepsy type 2 NIHRIO (HSRIC) ID: 11738 NICE ID: 9624 LAY SUMMARY Hypersomnia means excessive sleepiness and sleeping, when the person struggles to stay awake during the day and has great difficulty being awakened from sleep. When there is no clear cause, this condition is called idiopathic hypersomnia (IH). Narcolepsy is a rare long-term brain disorder that causes a person to suddenly fall asleep at inappropriate times. Sometimes narcolepsy is associated with temporary loss of muscle control that causes weakness and possible collapse (cataplexy). This type of narcolepsy is called Type 1 narcolepsy. When narcolepsy is not associated with cataplexy is called type 2 narcolepsy. Narcolepsy and IH are very similar conditions. Pentetrazol is a medicinal product that is being developed for the treatment of IH and narcolepsy type 2. Pentetrazol is administered orally and it acts by blocking the effect of a chemical substance called Gamma-Aminobutyric Acid (GABA). GABA is thought to play a role in promoting sleeping and is believed to be elevated in people with IH. If licensed, Pentetrazol will offer a new treatment option for patients with IH or narcolepsy type 2. This briefing reflects the evidence available at the time of writing. A version of the briefing was sent to the company for a factual accuracy check. The company was unavailable to provide comment. It is not intended to be a definitive statement on the safety, efficacy or effectiveness of the health technology covered and should not be used for commercial purposes or commissioning without additional information.
    [Show full text]
  • Chronic Intermittent Ethanol-Induced Switch of Ethanol Actions from Extrasynaptic to Synaptic Hippocampal
    The Journal of Neuroscience, February 8, 2006 • 26(6):1749–1758 • 1749 Neurobiology of Disease Chronic Intermittent Ethanol-Induced Switch of Ethanol Actions from Extrasynaptic to Synaptic Hippocampal GABAA Receptors Jing Liang,1,2 Nianhui Zhang,3 Elisabetta Cagetti,2 Carolyn R. Houser,3 Richard W. Olsen,2 and Igor Spigelman1 1Division of Oral Biology and Medicine, School of Dentistry, University of California, Los Angeles, and Departments of 2Molecular and Medical Pharmacology and 3Neurobiology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California 90095 Alcohol withdrawal syndrome (AWS) symptoms include hyperexcitability, anxiety, and sleep disorders. Chronic intermittent ethanol (CIE) treatment of rats with subsequent withdrawal of ethanol (EtOH) reproduced AWS symptoms in behavioral assays, which included tolerance to the sleep-inducing effect of acute EtOH and its maintained anxiolytic effect. Electrophysiological assays demonstrated a CIE-induced long-term loss of extrasynaptic GABAA receptor (GABAAR) responsiveness and a gain of synaptic GABAAR responsiveness of CA1 pyramidal and dentate granule neurons to EtOH that we were able to relate to behavioral effects. After CIE treatment, the ␣4 3ϩ subunit-preferring GABAAR ligands 4,5,6,7 tetrahydroisoxazolo[5,4-c]pyridin-3-ol, La , and Ro15-4513 (ethyl-8-azido-5,6-dihydro-5- methyl-6-oxo-4H-imidazo[1,5␣][1,4]benzodiazepine-3-carboxylate) exerted decreased effects on extrasynaptic currents but had in- creased effects on synaptic currents. Electron microscopy revealed an increase in central synaptic localization of ␣4 but not ␦ subunits within GABAergic synapses on the dentate granule cells of CIE rats. Recordings in dentate granule cells from ␦ subunit-deficient mice revealed that this subunit is not required for synaptic GABAAR sensitivity to low [EtOH].
    [Show full text]
  • Cogentin (Benztropine Mesylate) Injection Label
    COGENTIN® (benztropine mesylate injection) Rx Only DESCRIPTION Benztropine mesylate is a synthetic compound containing structural features found in atropine and diphenhydramine. It is designated chemically as 8-azabicyclo[3.2.1] octane, 3-(diphenylmethoxy)-,endo, methanesulfonate. Its empirical formula is C21H25NO•CH4O3S, and its structural formula is: Benztropine mesylate is a crystalline white powder, very soluble in water, and has a molecular weight of 403.54. COGENTIN (benztropine mesylate) is supplied as a sterile injection for intravenous and intramuscular use. Each milliliter of the injection contains: Benztropine mesylate…………………………………………………………………..1 mg Sodium chloride……………………………………………………….........................9 mg Water for injection q.s…………………………………………………………………..1 mL ACTIONS COGENTIN possesses both anticholinergic and antihistaminic effects, although only the former have been established as therapeutically significant in the management of parkinsonism. Page 1 of 7 Reference ID: 3296967 In the isolated guinea pig ileum, the anticholinergic activity of this drug is about equal to that of atropine; however, when administered orally to unanesthetized cats, it is only about half as active as atropine. In laboratory animals, its antihistaminic activity and duration of action approach those of pyrilamine maleate. INDICATIONS For use as an adjunct in the therapy of all forms of parkinsonism (see DOSAGE AND ADMINISTRATION). Useful also in the control of extrapyramidal disorders (except tardive dyskinesia – see PRECAUTIONS) due to neuroleptic drugs (e.g., phenothiazines). CONTRAINDICATIONS Hypersensitivity to any component of COGENTIN injection. Because of its atropine-like side effects, this drug is contraindicated in pediatric patients under three years of age, and should be used with caution in older pediatric patients. WARNINGS Safe use in pregnancy has not been established.
    [Show full text]
  • Tutu Toxicity: Three Case Reports of Coriaria Arborea Ingestion, Review
    THE NEW ZEALAND MEDICAL JOURNAL Journal of the New Zealand Medical Association Tutu toxicity: three case reports of Coriaria arborea ingestion, review of literature and recommendations for management Sally F Belcher, Tom R Morton Abstract We describe three cases of tutu berry (Coriaria arborea ) ingestion resulting in tonic- clonic seizures in two individuals and mild symptoms in the third. Tutu poisoning in humans appears to be a rare occurrence; the last reported case in the medical literature being over 40 years ago. We review the literature on tutu poisoning and recommend extending the period of observation for poisoned individuals from 8 hours to 12 hours or longer. We also recommend that prophylactic benzodiazepine use should be considered in those with mild to moderate symptoms of poisoning. Background There are about 30 species of Coriariaceae found around the world including southern Europe, eastern Asia, south and central America, and New Zealand.1 The six species native to New Zealand and the Chatham islands (Coriaria angustissim, C. arborea, C. lurida, C. plumosa, C. pteridoides and C. sarmentosa ) are all known by the name tutu 1 and are mostly deciduous shrubs found in grassland. There is variety in appearance and distribution as seen with Coriaria arborea, or “tree tutu”, which may become an evergreen tree growing to 6 metres in height and being found in coastal and montaine forest.2 The primary toxin, tutin , was discovered in 1870 3 and is found in all varieties of tutu 1,2 . It is a picrotoxin-like toxin which acts as an antagonist at amino acid receptors within the CNS, especially the medullary, cortical, respiratory, vasomotor, and autonomic centers 4.
    [Show full text]
  • Product Update Price List Winter 2014 / Spring 2015 (£)
    Product update Price list winter 2014 / Spring 2015 (£) Say to affordable and trusted life science tools! • Agonists & antagonists • Fluorescent tools • Dyes & stains • Activators & inhibitors • Peptides & proteins • Antibodies hellobio•com Contents G protein coupled receptors 3 Glutamate 3 Group I (mGlu1, mGlu5) receptors 3 Group II (mGlu2, mGlu3) receptors 3 Group I & II receptors 3 Group III (mGlu4, mGlu6, mGlu7, mGlu8) receptors 4 mGlu – non-selective 4 GABAB 4 Adrenoceptors 4 Other receptors 5 Ligand Gated ion channels 5 Ionotropic glutamate receptors 5 NMDA 5 AMPA 6 Kainate 7 Glutamate – non-selective 7 GABAA 7 Voltage-gated ion channels 8 Calcium Channels 8 Potassium Channels 9 Sodium Channels 10 TRP 11 Other Ion channels 12 Transporters 12 GABA 12 Glutamate 12 Other 12 Enzymes 13 Kinase 13 Phosphatase 14 Hydrolase 14 Synthase 14 Other 14 Signaling pathways & processes 15 Proteins 15 Dyes & stains 15 G protein coupled receptors Cat no. Product name Overview Purity Pack sizes and prices Glutamate: Group I (mGlu1, mGlu5) receptors Agonists & activators HB0048 (S)-3-Hydroxyphenylglycine mGlu1 agonist >99% 10mg £112 50mg £447 HB0193 CHPG Sodium salt Water soluble, selective mGlu5 agonist >99% 10mg £59 50mg £237 HB0026 (R,S)-3,5-DHPG Selective mGlu1 / mGlu5 agonist >99% 10mg £70 50mg £282 HB0045 (S)-3,5-DHPG Selective group I mGlu receptor agonist >98% 1mg £42 5mg £83 10mg £124 HB0589 S-Sulfo-L-cysteine sodium salt mGlu1α / mGlu5a agonist 10mg £95 50mg £381 Antagonists HB0049 (S)-4-Carboxyphenylglycine Competitive, selective group 1
    [Show full text]
  • At the Gabaa Receptor
    THE EFFECTS OF CHRONIC ETHANOL INTAKE ON THE ALLOSTERIC INTERACTION BE T WEEN GABA AND BENZODIAZEPINE AT THE GABAA RECEPTOR THESIS Presented to the Graduate Council of the University of North Texas in Partial Fulfillment of the Requirements For the Degree of MASTER OF SCIENCE By Jianping Chen, B.S., M.S. Denton, Texas May, 1992 Chen, Jianping, The Effects of Chronic Ethanol Intake on the Allsteric Interaction Between GABA and BenzodiazeDine at the GABAA Receptor. Master of Science (Biomedical Sciences/Pharmacology), May, 1992, 133 pp., 4 tables, 3.0 figures, references, 103 titles. This study examined the effects of chronic ethanol intake on the density, affinity, and allosteric modulation of rat brain GABAA receptor subtypes. In the presence of GABA, the apparent affinity for the benzodiazepine agonist flunitrazepam was increased and for the inverse agonist R015-4513 was decreased. No alteration in the capacity of GABA to modulate flunitrazepam and R015-4513 binding was observed in membranes prepared from cortex, hippocampus or cerebellum following chronic ethanol intake or withdrawal. The results also demonstrate two different binding sites for [3H]RO 15-4513 in rat cerebellum that differ in their affinities for diazepam. Chronic ethanol treatment and withdrawal did not significantly change the apparent affinity or density of these two receptor subtypes. ACKNOWLEDGEMENT I would like to express my sincere thanks to my major professor, Dr. Michael W. Martin. .I deeply appreciate his guidance and direction which initiated this study, and his kindness in sharing his laboratory facilities with me. His suggestions, patience, encouragement and support in the laboratory have contributed significantly to my understanding of the receptor mechanism of drug action.
    [Show full text]